article thumbnail

Clinical Trial Explores CBD’s Influence on Cannabis Safety

Veriheal

Serial plasma concentrations of THC and CBD were also measured. On the other hand, they observed a dose-response connection between CBD dose and plasma CBD concentration, with no noticeable effect on plasma THC concentrations. Fluctuations in the severity of psychotic symptoms (e.g., Gaia Herbs Hemp, and Joy Organics.

article thumbnail

FSD Pharma Inc. Announces Termination of FSD-201 Phase 2 Clinical Trial

Cannabis Law Report

Nasdaq:HUGE) (CSE:HUGE) (FRA:0K9) (the “ Company ” or “ FSD ”) announced today that it intends to terminate the Phase 2 clinical trial of ultra-micronized palmitoylethanolamide (“PEA”), or FSD-201, for use in treating COVID-19. TORONTO–(BUSINESS WIRE)–FSD Pharma Inc. About FSD Pharma. FSD Pharma Inc.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

The Cannabis Cancer Connection

Project CBD

United Kingdom-based GW Pharmaceuticals has produced the world’s first approved cannabis-based medicines for the UK, US, and European markets, Sativex® and Epidiolex®. GW Pharmaceuticals’ research on glioblastoma multiforme (GBM) is important and promising. Note: In May 2021, GW Pharmaceuticals was acquired by Jazz Pharmaceuticals.]

article thumbnail

Anebulo Pharmaceuticals Reports First Quarter Fiscal Year 2022 Financial Results and Provides a Business Update

Cannabis Law Report

AUSTIN, Texas–(BUSINESS WIRE)– Anebulo Pharmaceuticals, Inc. Completed manufacturing of ANEB-001 capsules for upcoming Phase 2 clinical trial. On track to commence Phase 2 proof-of-concept clinical trial with ANEB-001 for the treatment of acute cannabinoid intoxication by year-end.

article thumbnail

Anebulo Pharmaceuticals Names Biotechnology Industry Executive Simon Allen as CEO and Director

Cannabis Law Report

AUSTIN, Texas–(BUSINESS WIRE)–Anebulo Pharmaceuticals, Inc. I am so very proud of all Anebulo has achieved over the past 18 months, including building out a highly effective team, securing new intellectual property protection, preparing and starting a proof-of-concept clinical trial, advancing regulatory discussions with the U.S.

article thumbnail

Virpax Pharmaceuticals Recaps Milestones and Highlights Product Portfolio

Cannabis Law Report

–(BUSINESS WIRE)– #pharma –Virpax ® Pharmaceuticals, Inc. (“Virpax” or the “Company”) (NASDAQ:VRPX) achieved significant milestones relating to its pipeline of product candidates as of the end of 2021, which are summarized below. “I About Virpax Pharmaceuticals. BERWYN, Pa.–(BUSINESS

article thumbnail

‘The most meaningful cannabis reform in decades’: Experts weigh in on new DEA rules

The Cannigma

‘Junk’ cannabis ‘ill-suited for clinical trials’. The cannabis grown at the University of Mississippi “is junk, ill-suited for clinical trials, and genetically closer to hemp than the marijuana available from dispensaries and used by Americans nationwide,” according to the lawsuit. Shutterstock).

DEA 133